Johnson & Johnson Stock Price and Value Analysis

Johnson & Johnson (NYSE:JNJ) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Johnson & Johnson to reach your target.

Target type

JNJ Free Cash Flow Trend

Free Cash Flow trendline for JNJ
Free Cash Flow trendline for Johnson & Johnson
CSV

Based on historical returns, we believe that Johnson & Johnson can grow its free cash at a rate of about 11%. That's positive!

AdvantagesDisadvantages
  • This company is a well-established bedrock.
  • This company has amazingly consistent growth!
  • This company is making money at a great rate!
  • This company has an average dividend yield.
  • This stock looks overpriced.

Inside the JNJ Numbers

JNJ Price
(Johnson & Johnson stock price per share)
$270.47
[?] JNJ Fair Price
(based on intrinsic value)
$240.14
[?] JNJ Safety Price (based on a variable margin of safety) $204.12
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 102% higher than other Healthcare stocks
[?] PE Ratio versus Industry 40% higher than other Drug Manufacturers - General stocks
[?] Cash Yield 3.01%
[?] Free Cash Flow Jitter 7%
[?] Dividend Yield 1.98% (tax impact)
Shares Shorted 17,068,289

Insider Activity Summary

No open-market insider buys or sells are recorded in the six months to 2026-11-22.

The six months before that had 0 buys and 2 sales.

Recent Insider Activity

Open-market buys and sells reported by Johnson & Johnson's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2025-11-26 JOHNSON & JOHNSON Sell 6,337 $10.03
2025-11-24 JOHNSON & JOHNSON Sell 2,200 $10.06
2025-11-21 JOHNSON & JOHNSON Sell 500 $10.00
2025-11-12 JOHNSON & JOHNSON Sell 1,000 $10.00
2025-11-07 JOHNSON & JOHNSON Sell 200 $10.00
2025-11-06 JOHNSON & JOHNSON Sell 52,332 $10.21
2024-02-16 JOHNSON & JOHNSON Sell 3,725 $25.81

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 17,068,289 shares shorted. With 2,403,554,862 shares available for purchase and an average trading volume over the past 10 trading days of 7,851,080, it would take at least 2.2 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 200406 12,080
2008 200406 11,968
2009 200406 13,780
2010 200406 13,696
2011 200406 11,568
2012 200406 12,668
2013 200406 14,580
2014 200406 15,606
2015 200406 16,249
2016 200406 15,381
2017 200406 17,601
2018 200406 18,731
2019 200406 19,989
2020 200406 20,132
2021 200406 19,921
2022 200406 17,559
2023 200406 18,981
2024 200406 20,271
2025 200406 20,238

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 16 fiscal years from 2010 to 2025 with positive net income, operating cash flow totaled $326,939 million against net income of $257,234 million, or 1.27 times.

In 2025, operating cash flow was 0.92 times net income, compared with 1.36 times for the earliest three years (2010 to 2012).

In 2025, capital expenditures were $4,832 million, 19.7% of operating cash flow of $24,530 million, which leaves an estimated $19,698 million after capex. Across the 16 years with reported capex, it averaged 17.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Cash conversion in 2025 was 0.92, at least 0.25 under the 1.36 earliest three-year ratio. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2010 13,334 16,385 2,384 1.23
2011 9,672 14,298 2,893 1.48
2012 10,853 15,396 2,934 1.42
2013 13,831 17,414 3,595 1.26
2014 16,323 18,710 3,714 1.15
2015 15,409 19,569 3,463 1.27
2016 16,540 18,767 3,226 1.13
2017 1,300 21,056 3,279 16.20
2018 15,297 22,201 3,670 1.45
2019 15,119 23,416 3,498 1.55
2020 14,714 23,536 3,347 1.60
2021 20,878 23,410 3,652 1.12
2022 17,941 21,194 4,009 1.18
2023 35,153 22,791 4,543 0.65
2024 14,066 24,266 4,424 1.73
2025 26,804 24,530 4,832 0.92

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $188,802 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $106,144 million, 56.2% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.

In 10 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $54,102 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $18,334 million, 90.6% of estimated free cash flow of $20,238 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 15,381 8,621 8,979 17,600 114.4%
2017 17,601 8,943 6,358 15,301 86.9%
2018 18,731 9,494 5,868 15,362 82.0%
2019 19,989 9,917 6,746 16,663 83.4%
2020 20,132 10,481 3,221 13,702 68.1%
2021 19,921 11,032 3,456 14,488 72.7%
2022 17,559 11,682 6,035 17,717 100.9%
2023 18,981 11,770 5,054 16,824 88.6%
2024 20,271 11,823 2,432 14,255 70.3%
2025 20,238 12,381 5,953 18,334 90.6%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $71,890 million in 2016 and $94,193 million in 2025, a compound annual growth rate of 3.0% over 9 years.

Revenue rose 6.0% from 2024 to 2025.

Our estimated free cash flow was $20,238 million in 2025, 21.5% of revenue. In 2016 the estimated margin was 21.4%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2016 71,890 15,381 21.4%
2017 76,450 17,601 23.0%
2018 81,581 18,731 23.0%
2019 82,059 19,989 24.4%
2020 82,584 20,132 24.4%
2021 78,740 19,921 25.3%
2022 79,990 17,559 22.0%
2023 85,159 18,981 22.3%
2024 88,821 20,271 22.8%
2025 94,193 20,238 21.5%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $19,709 million against total liabilities of $117,666 million, or 16.7% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 59.1% of total assets in 2025, compared with 49.9% in 2008, an increase of 9.1 percentage points.

Stockholders equity was $81,544 million in 2025, compared with $42,511 million in 2008, a rise of 91.8%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 16.1% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 84,912 10,768 42,401 42,511
2009 94,682 15,810 44,094 590
2010 102,908 19,355 46,329 56,579
2011 113,644 24,542 56,564 57,080
2012 121,347 14,911 56,521 64,826
2013 132,683 20,927 58,630 74,053
2014 130,358 14,523 60,606 69,752
2015 133,411 13,732 62,261 71,150
2016 141,208 18,972 70,790 70,418
2017 157,303 17,824 97,143 60,160
2018 152,954 18,107 93,202 59,752
2019 157,728 17,305 98,257 59,471
2020 174,894 13,985 111,616 63,278
2021 182,018 14,487 107,995 74,023
2022 187,378 12,889 110,574 76,804
2023 167,558 21,859 98,784 68,774
2024 180,104 24,105 108,614 71,490
2025 199,210 19,709 117,666 81,544

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $270.47, our model's value equals that price if free cash flow grows an average of 13.3 percent a year over the 10 projection years. Our model assumes 11.5 percent a year for this stock, so the price implies growth of 13.3 percent, which is above the 11.5 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $19,590 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $216.38 9.9%
Current price $270.47 13.3%
20 percent above the current price $324.56 16.0%
Our model (stored fair price) $240.14 11.5%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Johnson & Johnson is priced at $270.47, above our fair value estimate of $240.14 and its safe value of $204.12.

Free cash flow was positive in all 19 fiscal years we have for Johnson & Johnson under its current SEC filer.

Johnson & Johnson's average free cash flow rose sharply, from $12,609 million in its earliest three years to $19,830 million in its latest three.

Year-to-year variability in free cash flow is unusually steady, measured at 7%.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

Its dividend yield is 1.98%.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 102% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 40% above the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Johnson & Johnson, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Johnson & Johnson (JNJ) 651,105 41.0 2.0% 3.0% 13% above
Abbott Laboratories (ABT) 178,390 38.4 2.4% 1.9% 49% above
Pfizer (PFE) 156,176 39.1 7.8% 11.6% 63% below
Bristol-Myers Squibb Company (BMY) 120,192 13.0 4.3% 1.2% 85% above
Regeneron Pharmaceuticals (REGN) 95,243 20.4 0.4% 0.5% 133% above
Teva Pharmaceutical Industries Limited (TEVA) 44,970 89.6 - 13.5% 47% below
Zoetis (ZTS) 32,144 13.5 2.6% - 865% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 200406.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: JNJ annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in JNJ

Does Johnson & Johnson have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: JNJ

This example shows how we apply the Trendshare checklist to JNJ: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 270.47
    • Market cap: $651B
    • EPS: 6.59
  2. Step 2 — Valuation checks

    • P/E: 41.042
    • FCF yield: 3.0%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.